Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evalsuating BAT8007,an antibody-drug conjugate (ADC) that targets Nectin-4. The multicenter,open-label Phase 1 clinica...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evalsuating BAT8008,an antibody-drug conjugate (ADC) that targets Trop2. The multicenter,open-label Phase 1 clinical s...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evalsuating BAT8010,an antibody-drug conjugate (ADC) that targets HER2. The multicenter, open-labelPhase 1 clinical st...
